Exploring Non-Hormonal Treatments for Managing Menopausal Symptoms
-
By
-
Laura Ungar
-
November 15, 2025
Clinical Scorecard: Exploring Non-Hormonal Treatments for Managing Menopausal Symptoms
At a Glance
| Category | Detail |
|---|---|
| Condition | Menopausal symptoms including hot flashes, night sweats, sleep problems, brain fog, and vaginal dryness |
| Key Mechanisms | Decline in estrogen and progesterone production during menopause affecting body temperature regulation, cardiovascular health, and other systems |
| Target Population | Women experiencing menopausal symptoms, especially those who cannot or choose not to use hormone therapy due to medical history or personal preference |
| Care Setting | Outpatient and primary care settings, including women’s health clinics |
Key Highlights
- Non-hormonal options include lifestyle changes, prescription medications, and behavioral therapies.
- New FDA-approved drugs (Veozah and Lynkuet) target brain pathways controlling hot flashes but have potential side effects.
- Cognitive behavioral therapy and clinical hypnosis show promise in reducing symptom burden.
Guideline-Based Recommendations
Diagnosis
- Assess menopausal symptoms and medical history to determine suitability for hormone therapy.
- Identify contraindications such as breast cancer history, severe liver disease, cardiovascular events, or blood clots.
Management
- Encourage lifestyle modifications: increased physical activity (aerobic and strength training), plant-forward diet, weight management, and avoidance of dietary triggers like caffeine and alcohol.
- Consider non-hormonal prescription medications such as antidepressants, oxybutynin for overactive bladder and hot flashes, and neurokinin receptor antagonists (Veozah, Lynkuet).
- Use over-the-counter lubricants for vaginal dryness.
- Offer cognitive behavioral therapy and consider clinical hypnosis to reduce symptom impact.
Monitoring & Follow-up
- Monitor for side effects of non-hormonal medications, including liver injury risk with Veozah and fatigue or sleep disturbances with Lynkuet.
- Evaluate effectiveness and tolerability of antidepressants and oxybutynin.
- Regularly assess cardiovascular health and lifestyle adherence.
Risks
- Hormone therapy contraindicated in patients with hormone-sensitive breast cancer, severe liver disease, history of heart attack, stroke, or blood clots.
- Veozah carries a rare but serious risk of liver injury.
- Lynkuet may cause fatigue and difficulty staying awake.
- Antidepressants can cause weight gain at higher doses.
- Oxybutynin may cause dry mouth and incomplete bladder emptying.
Patient & Prescribing Data
Women with menopausal symptoms who cannot or prefer not to use hormone therapy, including breast cancer survivors and those with cardiovascular or liver disease risks.
Combination of lifestyle changes and non-hormonal medications can significantly improve symptoms; individualized treatment plans are essential.
Clinical Best Practices
- Engage patients in shared decision-making about treatment options.
- Promote comprehensive lifestyle interventions alongside pharmacologic treatments.
- Screen for contraindications before prescribing hormone therapy.
- Educate patients about potential side effects of non-hormonal medications.
- Incorporate behavioral therapies to reduce symptom burden and improve quality of life.
References
- Mayo Clinic Center for Women’s Health
- U.S. Food and Drug Administration - Veozah and Lynkuet Approvals
- The North American Menopause Society
Based on findings from:
A look at nonhormonal options for menopause symptoms
Laura Ungar. Associated Press Health, 2025.
https://apnews.com/article/menopause-hormone-therapy-hot-flashes-0f3258f1762e1fb3c9a6f7205a43e66e
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
